Cepheid Q1 Revenues Rise 16 Percent; Firm Gets Chinese FDA OK for Xpert TB Test | GenomeWeb

NEW YORK (GenomeWeb News) — Cepheid said after the close of the market Thursday that its first quarter revenues grew 16 percent year over year driven by 26 percent growth in its clinical business.

In addition, the company disclosed during a conference call following the earnings release that it received Chinese Food and Drug Administration clearance for its Xpert MTB/RIF test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.